HIV Antiretrovirals
Single-tablet regimens (STRs) and combination antiretroviral therapies that suppress HIV viral load to undetectable levels.
How HIV Antiretrovirals Work
Modern HIV treatment uses 2-3 drugs combined in one pill. Integrase strand transfer inhibitors (INSTIs like bictegravir in Biktarvy) block HIV from inserting its genetic material into human cells. NRTIs (tenofovir, emtricitabine) block the virus from copying its RNA into DNA. The combination prevents resistance. Once-daily single-tablet regimens achieve >95% viral suppression.
HIV Antiretrovirals — Ranked by Cost Per Claim (Cheapest First)
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Descovy | Emtricitabine/TAF | $2,418.00 | Yes |
| 2 | Dovato | Dolutegravir/Lamivudine | $2,910.00 | Yes |
| 3 | Symtuza | Darunavir/Cobicistat/Emtricitabine/TAF | $3,532.00 | Yes |
| 4 | Triumeq | Dolutegravir/Abacavir/Lamivudine | $3,580.00 | Yes |
| 5 | Genvoya | Elvitegravir/Cobicistat/Emtricitabine/TAF | $3,619.00 | Yes |
| 6 | Biktarvy | Bictegravir/Emtricitabine/TAF | $3,746.00 | No |
| 7 | Juluca | Dolutegravir/Rilpivirine | $3,831.00 | Yes |
| 8 | Cabenuva | Cabotegravir/Rilpivirine | $6,593.00 | Yes |
Potential Savings
HIV drugs remain expensive because patent protection is strong and patients require lifelong treatment. Generic Triumeq launched recently at ~$2,800/month. Biktarvy ($3,746/claim) has no generic expected before 2033. Patient assistance programs cover most uninsured patients.
Key Facts
- 1.1.2 million Americans live with HIV; 36,000 new diagnoses per year
- 2.HIV treatment is lifelong — stopping medication allows the virus to rebound
- 3.Biktarvy ($3,746/claim) is the most prescribed HIV drug with $3.8B in Medicare spending
- 4.All major HIV drugs cost $2,400-3,800 per month without insurance
- 5.Generic competition is limited — most patent expirations are 2030+
- 6.Patient assistance programs and 340B pricing make HIV drugs accessible to most patients
Frequently Asked Questions
The cheapest option is Generic Triumeq (dolutegravir/abacavir/lamivudine) at $2800 per claim. HIV drugs remain expensive because patent protection is strong and patients require lifelong treatment. Generic Triumeq launched recently at ~$2,800/month. Biktarvy ($3,746/claim) has no generic expected before 2033. Patient assistance programs cover most uninsured patients.
Modern HIV treatment uses 2-3 drugs combined in one pill. Integrase strand transfer inhibitors (INSTIs like bictegravir in Biktarvy) block HIV from inserting its genetic material into human cells. NRTIs (tenofovir, emtricitabine) block the virus from copying its RNA into DNA. The combination prevents resistance. Once-daily single-tablet regimens achieve >95% viral suppression.
All spending data comes from the CMS Medicare Part D Drug Spending Dashboard. Patent and generic information comes from the FDA Orange Book. Prices shown are average cost per 30-day supply claim under Medicare Part D.